2025.06.13 (금)

  • 구름많음동두천 17.6℃
  • 맑음강릉 20.3℃
  • 구름많음서울 18.2℃
  • 맑음대전 18.5℃
  • 맑음대구 19.0℃
  • 맑음울산 20.0℃
  • 맑음광주 18.4℃
  • 맑음부산 19.1℃
  • 맑음고창 18.4℃
  • 맑음제주 21.3℃
  • 구름많음강화 15.3℃
  • 구름조금보은 17.3℃
  • 맑음금산 18.1℃
  • 맑음강진군 18.7℃
  • 구름조금경주시 20.7℃
  • 맑음거제 19.7℃
기상청 제공
닫기

English

'Owner 3rd Generation' Jeong Gi-seon HD Hyundai Group Vice Chairman, Promoted to Senior Vice Chairman... Vice Chairman Cho Seok, Presidents Kim Jae-eul, Kim Young-gi, and Song Myung-jun 'Promoted'

 

[News Space=Reporter seungwon lee] HD Hyundai carried out its 2024 executive appointments on the 14th.

 

In the personnel changes that day, Vice Chairman Jeong Gi-seon was promoted to Senior Vice Chairman, and President Cho Seok of HD Hyundai Electric was promoted to Vice Chairman.

 

Kim Jae-eul, Vice President of Shipbuilding Business at HD Hyundai Heavy Industries, has been promoted to President as CEO of HD Hyundai Samho, and Song Myung-joon, Vice President of Finance Support Office at HD Hyundai, has been promoted to President as CEO of HD Hyundai Oilbank. At HD Hyundai Oilbank, Vice President Jeong Im-ju, who is currently in charge of the Safety Production Headquarters, has been appointed as Co-CEO with President Song Myung-joon. Vice President Kim Young-ki has been promoted to President as CEO of HD Hyundai Electric.

 

The new CEOs announced on this day will be officially appointed as CEOs after a general shareholders' meeting and board of directors meeting.

 

HD Hyundai Samho CEO Kim Jae-eul was born in 1965 (59 years old). He graduated from the Department of Navigation at Korea Maritime and Ocean University. He is a shipbuilding expert with extensive experience in design and production at Hyundai Heavy Industries. After serving as the head of the Technology Headquarters and the Production Headquarters at Hyundai Heavy Industries, he is currently the head of the shipbuilding division at HD Hyundai Heavy Industries.

 

HD Hyundai Oilbank President Song Myung-joon was born in 1969 (age 55), graduated from Yonsei University’s Department of Business Administration, worked in finance and business planning at Hyundai Heavy Industries and Hyundai Oilbank, and is currently the head of HD Hyundai’s Financial Support Office. HD Hyundai Oilbank’s co-CEO, Vice President Jeong Im-ju, was born in 1969 (age 55), graduated from Yonsei University’s Department of Chemical Engineering, worked as a production process and technology engineer at Hyundai Oilbank’s Daesan Plant, served as the CEO of Hyundai Chemical, and is currently the head of HD Hyundai Oilbank’s Safety Production Headquarters.

 

HD Hyundai Electric CEO Kim Young-ki was born in 1966 (age 58), graduated from Kyunghee University, and received a master's degree from the University of Texas. He is recognized as an expert in this field, having worked in various fields including product development, sales, and production, starting at the Electric Power Equipment Research Institute.

 

An HD Hyundai official stated, “We have carried out personnel changes at the executive level in order to actively respond to the rapidly changing business environment, including changes in the business environment following the U.S. presidential election, changes in the international situation including the war in Ukraine, and fluctuations in oil prices and exchange rates.”

 

The official said, “2025 will be a year in which we will focus all our efforts on strengthening the competitiveness of our core businesses and securing future eco-friendly technologies.” He added, “This year, the shipbuilding division showed good performance with stable securing of operating volume and process stability, but going forward, we will thoroughly prepare for economic downturns by expanding into overseas markets including the U.S. as well as developing and internalizing ultra-gap technologies.”

 

In addition, he said, “The construction equipment division will continue to implement management innovations such as completing the development of next-generation new models, completing the new Ulsan plant, and reorganizing to secure synergy. The oil refining and petrochemical division had a difficult year due to reduced refining margins and a deteriorating petrochemical market, but with the appointment of new management, we will make various management improvement efforts such as innovating the organizational culture and improving the financial structure through cost reduction.”

 

Vice Chairman Jeong Ki-seon, who was promoted to Senior Vice Chairman in the personnel reshuffle that day, is expected to focus more on personally taking charge of the group's key tasks and leading the way in discovering the group's future growth engines, eco-friendly and digital technology innovation, and spreading a new corporate culture.

 

Meanwhile, HD Hyundai plans to carry out follow-up executive personnel changes soon following the executive appointments made today. 

이승원 기자의 전체기사 보기

저작권자 © 뉴스스페이스(NewsSpace) 무단전재 및 재배포 금지

배너
배너
배너

관련기사

93건의 관련기사 더보기

이 시각 추천뉴스

Fair Trade Commission Gives Hyosung Group a Free Pass for Its ‘Abusive’ Technology Requirements… Will It Be Over if They Just Pay 3 Billion Won?

[News Space=Reporter seungwon lee] The Fair Trade Commission has initiated a 'consent resolution' procedure to provide an opportunity for voluntary correction without determining whether Hyosung Group, which is under investigation for unfairly requesting technical data from subcontractors, has violated the law. Hyosung proposed a 3 billion won win-win plan, and the Fair Trade Commission accepted it, opening the way for a quick conclusion to the case. This decision is raising controversy over whether the consent system is being reduced to an 'indulgence.' Hyosung, unreasonably demanding technic

Beauty regulators in Asia gather at ‘Korea Kolmar’… Visit ‘K-Beauty R&D Heart’ to check Korea’s competitiveness

[News Space=Reporter seungwon lee] High-ranking government officials in charge of cosmetics regulations in Asian countries visited Kolmar Korea. With K-beauty recently gaining popularity in the global market, they wanted to directly check out Kolmar Korea’s global research and development system and hear opinions on exports. Korea Kolmar announced on the 2nd that cosmetics regulatory authorities from major Asian countries visited Korea Kolmar’s General Technology Center on the 30th of last month. The visit was attended by about 20 people, including regulatory authorities from 7 Asian countries

Human division 'Samsung Bio' catches three rabbits... Bio global super gap, strengthening of Lee Jae-yong's control, asset value reevaluation 'a stroke of genius'

[News Space=Reporter seungwon lee] Samsung BioLogics is drastically reorganizing its business structure through a spin-off. On the 22nd, Samsung BioLogics announced through a public disclosure that it will split the company into the surviving corporation, ‘Samsung BioLogics’, which will be in charge of the contract development and manufacturing organization (CDMO) business, and the newly established corporation, ‘Samsung Epi Holdings’, which will act as an investment and holding company for biosimilar and new drug development. This split is a strategic decision to strengthen the expertise and

Lee Hae-jin, who went to Taiwan, met Jensen Huang, and the ‘AI alliance’ began in earnest… Naver and Nvidia ‘discuss’ cooperation on Sovereign AI

[News Space=Reporter seungwon lee] Naver Chairman Lee Hae-jin met with NVIDIA CEO Jensen Huang in Taiwan and signaled a new phase in the global AI leadership competition. This meeting was held during Asia's largest IT exhibition, 'Computex 2025', and NVIDIA's cloud partner event, 'NPC Summit', and the discussion on 'Sovereign AI' cooperation, which combines Naver's AI strategy and NVIDIA's infrastructure, emerged as a key agenda. Naver executives mobilize to attack Southeast Asia AI market in earnest Chairman Lee Hae-jin visited Taiwan with key executives, including Naver CEO Choi Soo-yeon and

Osstem Pharma participates in China Beauty Expo… Viewsen fever ‘hot’, global strategy ‘accelerates’

[News Space=Reporter seungwon lee] Osstem Pharma (CEO Moon Byeong-jeom), a subsidiary of Osstem Implant, announced that it received enthusiastic interest and response by introducing an exhibition booth for its premium oral care brand 'Viewsen' at the 'China Beauty Expo 2025 (CBE)' held at the Shanghai International Expo Center from May 12 to 14. CBE is the largest beauty trade show in Asia. This year, in its 29th year, over 3,500 companies from 80 countries around the world opened booths and attracted over 500,000 visitors. Osstem Pharma set up a brand promotion booth centered around the Views

Novartis, Profitability Regresses Despite Sales Increase… Net Income Approaching Dividends, Patent Infringement Lawsuits, Cash Assets 0 Won 'Risk'

[News Space=Reporter seungwon lee] Despite the increase in sales in 2024, Novartis Korea (CEO Yoo Byung-jae) saw its profitability decline as both operating profit and net profit decreased. The operating profit ratio also fell to 3.7%. In addition, short-term borrowings increased and cash assets remain at 0 won, making liquidity management weak. The scale of purchases and debts with special related parties (head office, etc.) is large, and the financial structure has improved somewhat due to inventory asset reduction and restructuring (dramatic reduction in retirement benefits), but the group

Celltrion Signs Contract with Large US PBM for 'Stekima' Listing… Full-scale Expansion of Reimbursement Coverage

[News Space=Reporter seungwon lee] Celltrion has successfully expanded its coverage by signing a formulary listing contract for its autoimmune disease treatment drug 'Steqeyma' (ingredient name: ustekinumab) with one of the top five prescription drug benefit managers (PBM) in the United States. As Celltrion secures the private insurance area under the jurisdiction of the PBM through this contract, Stekima is scheduled to receive a refund starting July 1. This contract is the second achievement that Celltrion has made with a large US PBM for the listing of Stekima in the formulary. Prior to thi

Daewon Pharmaceutical Risk (Part 4): From ‘Domestic New Drug Myth’ to ‘Bad Company’ Stigma… 4 Consecutive Patent Losses, Quality Risk, and the ‘Bare Face’ of Family Management

[News Space=Reporter seungwon lee] Daewon Pharmaceutical, once the pride of domestic new drugs, has lost four consecutive patent lawsuits for ‘Pelubi’ from the first trial to the Supreme Court, exposing its management incompetence and structural risks at once. In recent years, Daewon Pharmaceutical has been criticized as a typical ‘bad company’ due to repeated investigations by the Ministry of Food and Drug Safety and the National Tax Service, as well as repeated defeats in court. ◆ Four consecutive patent lawsuit losses… The fall of the Pelubi myth Daewon Pharmaceutical’s domestic new drug ‘P

“Risk to subcontractor, profit to general contractor” Hyundai-Kia industrial accidents reveal their true colors… ‘Conveyor belt of death’ is ongoing

[News Space=Reporter seungwon lee] The symbol of Korean manufacturing: Hyundai and Kia Motors factories. The workers there are called “new production workers” with hundreds of millions of won in annual salaries, but behind the splendid facade, there are industrial accidents, occupational diseases, and the tears of subcontracted workers. Even more shocking is the tyranny of Hyundai and Kia Motors, which evades all responsibility with their powerful power and capital. Over the past five years, more than 2,061 people were injured, and 28 people lost their lives… “Passing responsibility to subcont

많이 본 뉴스

더보기